JP2025000628A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2025000628A5 JP2025000628A5 JP2024151952A JP2024151952A JP2025000628A5 JP 2025000628 A5 JP2025000628 A5 JP 2025000628A5 JP 2024151952 A JP2024151952 A JP 2024151952A JP 2024151952 A JP2024151952 A JP 2024151952A JP 2025000628 A5 JP2025000628 A5 JP 2025000628A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- protein
- domain
- nkp46
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 62
- 229920001184 polypeptide Polymers 0.000 claims 60
- 102000004196 processed proteins & peptides Human genes 0.000 claims 60
- 108090000623 proteins and genes Proteins 0.000 claims 44
- 102000004169 proteins and genes Human genes 0.000 claims 44
- 239000000427 antigen Substances 0.000 claims 19
- 102000036639 antigens Human genes 0.000 claims 19
- 108091007433 antigens Proteins 0.000 claims 19
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 101000589301 Homo sapiens Natural cytotoxicity triggering receptor 1 Proteins 0.000 claims 6
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 claims 6
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 claims 6
- 102000050738 human NCR1 Human genes 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 5
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims 2
- 239000000539 dimer Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 102000053350 human FCGR3B Human genes 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 210000000822 natural killer cell Anatomy 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 101150019418 IGHV4-30-4 gene Proteins 0.000 claims 1
- 101150050798 IGKV1-39 gene Proteins 0.000 claims 1
- 101000589304 Macaca fascicularis Natural cytotoxicity triggering receptor 1 Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102000025171 antigen binding proteins Human genes 0.000 claims 1
- 108091000831 antigen binding proteins Proteins 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 239000000833 heterodimer Substances 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000013638 trimer Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562271474P | 2015-12-28 | 2015-12-28 | |
| US62/271,474 | 2015-12-28 | ||
| PCT/EP2016/081953 WO2017114694A1 (en) | 2015-12-28 | 2016-12-20 | VARIABLE REGIONS FOR NKp46 BINDING PROTEINS |
| JP2018552124A JP7091250B2 (ja) | 2015-12-28 | 2016-12-20 | ＮＫｐ４６結合タンパク質の可変領域 |
| JP2022096649A JP7551693B2 (ja) | 2015-12-28 | 2022-06-15 | ＮＫｐ４６結合タンパク質の可変領域 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022096649A Division JP7551693B2 (ja) | 2015-12-28 | 2022-06-15 | ＮＫｐ４６結合タンパク質の可変領域 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025000628A JP2025000628A (ja) | 2025-01-07 |
| JP2025000628A5 true JP2025000628A5 (https=) | 2025-04-14 |
Family
ID=57796296
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018552124A Active JP7091250B2 (ja) | 2015-12-28 | 2016-12-20 | ＮＫｐ４６結合タンパク質の可変領域 |
| JP2022096649A Active JP7551693B2 (ja) | 2015-12-28 | 2022-06-15 | ＮＫｐ４６結合タンパク質の可変領域 |
| JP2024151952A Pending JP2025000628A (ja) | 2015-12-28 | 2024-09-04 | ＮＫｐ４６結合タンパク質の可変領域 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018552124A Active JP7091250B2 (ja) | 2015-12-28 | 2016-12-20 | ＮＫｐ４６結合タンパク質の可変領域 |
| JP2022096649A Active JP7551693B2 (ja) | 2015-12-28 | 2022-06-15 | ＮＫｐ４６結合タンパク質の可変領域 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US11001629B2 (https=) |
| EP (1) | EP3397645B1 (https=) |
| JP (3) | JP7091250B2 (https=) |
| CN (2) | CN115925933A (https=) |
| AU (1) | AU2016383475B2 (https=) |
| CA (1) | CA3007898A1 (https=) |
| WO (1) | WO2017114694A1 (https=) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6822849B2 (ja) * | 2014-06-27 | 2021-01-27 | イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． | 多重特異的ＮＫｐ４６結合タンパク質 |
| US9767555B2 (en) * | 2015-01-05 | 2017-09-19 | Case Western Reserve University | Disease characterization from fused pathology and radiology data |
| WO2016207278A1 (en) * | 2015-06-23 | 2016-12-29 | Innate Pharma | Multispecific nk engager proteins |
| AU2016299166B2 (en) | 2015-07-24 | 2022-03-31 | Innate Pharma | Methods for detecting tissue infiltrating NK cells |
| CN115925933A (zh) | 2015-12-28 | 2023-04-07 | 依奈特制药公司 | NKp46结合蛋白的可变区 |
| FR3061716B1 (fr) * | 2017-01-06 | 2019-05-17 | Elsalys Biotech | Nouveaux composes ciblant le cd160 humain |
| WO2018138032A2 (en) | 2017-01-24 | 2018-08-02 | Innate Pharma | NKp46 BINDING AGENTS |
| SG11201907299XA (en) | 2017-02-08 | 2019-09-27 | Dragonfly Therapeutics Inc | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| IL268755B2 (en) | 2017-02-20 | 2025-12-01 | Dragonfly Therapeutics Inc | Proteins that bind her2, nkg2d, and cd16 |
| AU2018308088B2 (en) | 2017-07-25 | 2025-05-29 | Truebinding, Inc. | Treating cancer by blocking the interaction of TIM-3 and its ligand |
| AU2018371114A1 (en) | 2017-11-21 | 2020-05-07 | Innate Pharma | Multispecific antigen binding proteins |
| EA202091887A1 (ru) | 2018-02-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Комбинированная терапия рака с применением мультиспецифических связывающих белков, которые активируют естественные клетки-киллеры |
| DK3749346T3 (da) | 2018-02-08 | 2024-09-09 | Dragonfly Therapeutics Inc | Antistof variable domænekombinationer rettet mod nkg2d-receptoren |
| WO2019164930A1 (en) | 2018-02-20 | 2019-08-29 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use |
| CA3099308A1 (en) | 2018-05-21 | 2019-11-28 | Compass Therapeutics Llc | Compositions and methods for enhancing the killing of target cells by nk cells |
| CN113101364B (zh) | 2018-05-29 | 2023-12-01 | 康诺亚生物医药科技（成都）有限公司 | 一种自免疫抑制剂的开发和应用 |
| WO2020033630A1 (en) | 2018-08-08 | 2020-02-13 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
| US12378318B2 (en) | 2018-08-08 | 2025-08-05 | Dragonfly Therapeutics, Inc. | Proteins binding NKG2D, CD16 and a tumor-associated antigen |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| AU2020214796A1 (en) | 2019-01-30 | 2021-07-29 | Truebinding, Inc. | Anti-Gal3 antibodies and uses thereof |
| EP3938405A4 (en) * | 2019-03-20 | 2022-12-28 | Javelin Oncology, Inc. | ANTI-ADAM12 ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS, AND COMPOSITIONS AND METHODS THEREOF |
| US11896619B2 (en) | 2020-03-10 | 2024-02-13 | Massachusetts Institute Of Technology | Compositions and methods for immunotherapy of NPM1c-positive cancer |
| JP2023520587A (ja) * | 2020-04-06 | 2023-05-17 | イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム エルティーディー． | 癌及び感染症の治療のためのＮＫｐ４６に対する抗体及びそのコンストラクト |
| MX2022013944A (es) | 2020-05-06 | 2022-11-30 | Dragonfly Therapeutics Inc | Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a). |
| CN113637074B (zh) * | 2020-05-11 | 2024-09-24 | 上海怀越生物科技有限公司 | NKp46抗体及其制备方法和应用 |
| WO2021242776A2 (en) | 2020-05-26 | 2021-12-02 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking galectin-3 |
| EP4173640A4 (en) * | 2020-06-30 | 2024-08-14 | GAIA BioMedicine Inc. | METHOD FOR STABILIZING THE BINDING OF AN ANTIBODY ON AN NK CELL AND ASSOCIATED USE |
| CN112029001B (zh) * | 2020-09-02 | 2022-09-06 | 南京北恒生物科技有限公司 | 靶向nk激活性受体的嵌合抗原受体 |
| MX2023007901A (es) * | 2020-12-31 | 2023-07-11 | Sanofi Sa | Acopladores de celulas asesinas naturales (nk) multifuncionales que se unen a nkp46 y a cd123. |
| JP2024508894A (ja) | 2021-03-03 | 2024-02-28 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｎｋｇ２ｄ、ｃｄ１６、及び腫瘍関連抗原に結合する多特異性結合タンパク質を使用して癌を治療する方法 |
| CN116964099A (zh) * | 2021-03-05 | 2023-10-27 | 上海齐鲁制药研究中心有限公司 | 针对NKp46的抗体及其应用 |
| MX2023011310A (es) | 2021-03-26 | 2023-10-05 | Innate Pharma | Anclajes de citocina para proteinas de celulas nk de union a nkp46. |
| US20250002601A1 (en) | 2021-06-09 | 2025-01-02 | Innate Pharma | Multispecific antibodies binding to cd20, nkp46, cd16 and conjugated to il-2 |
| BR112023025331A2 (pt) | 2021-06-09 | 2024-02-27 | Innate Pharma | Proteína multiespecífica, composição farmacêutica, célula recombinante, ácido nucleico ou conjunto de ácidos nucleicos, uso de uma proteína ou composição, métodos ou uso |
| EP4363443A4 (en) * | 2021-07-02 | 2025-08-06 | Laekna Therapeutics Shanghai Co Ltd | DEPLETION OF ACTIVATED LIVER STELLAR CELLS (HSCs) AND THEIR USES |
| CN115611984A (zh) * | 2021-07-16 | 2023-01-17 | 上海怀越生物科技有限公司 | NKp46抗体及其制备方法和应用 |
| US20250230246A1 (en) * | 2021-10-27 | 2025-07-17 | Samyang Biopharm Usa Inc. | Anti-mic antibodies with variant fc domains |
| EP4448095A1 (en) | 2021-12-14 | 2024-10-23 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling |
| WO2023143341A1 (en) * | 2022-01-25 | 2023-08-03 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animal with human or chimeric nkp46 |
| IL317227A (en) | 2022-05-27 | 2025-01-01 | Sanofi Sa | Combined natural killer (NK) cells bind to NKP46 and BCMA variants with FC engineering |
| CN116003595B (zh) * | 2022-07-11 | 2024-02-02 | 南方医科大学第三附属医院（广东省骨科研究院） | 靶向nk细胞nkp46受体的纳米抗体及其制备方法和应用 |
| US20260055188A1 (en) * | 2022-08-19 | 2026-02-26 | Shenghe (China) Biopharmaceutical Co., Ltd. | Bispecific antibody and use thereof |
| CN116003627B (zh) * | 2022-09-16 | 2025-05-13 | 四川大学华西医院 | NKG2D-NKp46细胞接合器分子及其用途 |
| WO2024208818A1 (en) | 2023-04-04 | 2024-10-10 | Innate Pharma | Modular chimeric antigen receptor |
| CN121511253A (zh) | 2023-04-24 | 2026-02-10 | 赛诺菲 | Cd123 nk细胞接合器用于治疗aml和相关障碍的用途 |
| CN121399268A (zh) * | 2023-06-14 | 2026-01-23 | 上海北恒生物科技有限公司 | 工程化的滋养细胞及其用途 |
| WO2025012704A1 (en) | 2023-07-13 | 2025-01-16 | Sanofi | Natural killer cells and cd123 nk cell engager combination therapy |
| AR134497A1 (es) | 2023-11-28 | 2026-01-21 | Sanofi Sa | Combiterapia multifuncional con activador de los linfocitos citolíticos naturales (nk) para tratar trastornos neoplásicos hemáticos |
| CN117442721B (zh) * | 2023-12-20 | 2024-03-15 | 苏州艾凯利元生物科技有限公司 | 一种包括nk细胞和nk细胞接合器分子的组合物 |
| WO2026055280A1 (en) | 2024-09-04 | 2026-03-12 | Sanofi | Interleukin 2 (il-2) and cd123 nk cell engager combination therapy |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2288307C (en) * | 1999-11-15 | 2012-05-15 | Universita Di Genova | Novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells and antibodies that identify the same |
| WO2004056392A1 (en) * | 2002-12-23 | 2004-07-08 | Innate Pharma | Pharmaceutical compositions having an effect on the proliferation of nk cells and a method using the same |
| WO2005000086A2 (en) * | 2003-06-30 | 2005-01-06 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | FRAGMENTS OF NKp44 AND NKp46 FOR TARGETING VIRAL-INFECTED AND TUMOR CELLS |
| WO2005105848A1 (en) * | 2004-04-30 | 2005-11-10 | Innate Pharma | Compositions and methods for enhancing nk cell activity |
| AU2006301163B2 (en) * | 2005-10-14 | 2012-02-23 | Innate Pharma | Compositions and methods for treating proliferative disorders |
| WO2009026660A1 (en) * | 2007-08-30 | 2009-03-05 | Walter And Eliza Hall Institute Of Medical Research | Dendritic cell marker and uses thereof |
| EP2507381A4 (en) * | 2009-12-04 | 2016-07-20 | Hoffmann La Roche | MULTISPECIFIC ANTIBODIES, ANTIBODY ANALOGS, COMPOSITIONS AND METHODS |
| TW201138821A (en) * | 2010-03-26 | 2011-11-16 | Roche Glycart Ag | Bispecific antibodies |
| US20140234342A1 (en) * | 2011-06-21 | 2014-08-21 | Innate Pharma | Nkp46-mediated nk cell tuning |
| DK2956482T3 (en) * | 2013-02-14 | 2017-10-16 | Innate Pharma | TREATMENT OF PERFECT T cell lymphoma |
| WO2015015489A1 (en) * | 2013-07-30 | 2015-02-05 | Biolinerx Ltd. | Antibody for treating diabetes and autoimmune diseases |
| AU2015229448B2 (en) * | 2014-03-11 | 2020-09-03 | The Board Of Trustees Of The Leland Stanford Junior University | Anti SIRP-alpha antibodies and Bi-specific Macrophage Enhancing antibodies |
| JP6822849B2 (ja) * | 2014-06-27 | 2021-01-27 | イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． | 多重特異的ＮＫｐ４６結合タンパク質 |
| WO2016207278A1 (en) * | 2015-06-23 | 2016-12-29 | Innate Pharma | Multispecific nk engager proteins |
| CN115925933A (zh) | 2015-12-28 | 2023-04-07 | 依奈特制药公司 | NKp46结合蛋白的可变区 |
| WO2018138032A2 (en) | 2017-01-24 | 2018-08-02 | Innate Pharma | NKp46 BINDING AGENTS |
-
2016
- 2016-12-20 CN CN202210862118.XA patent/CN115925933A/zh active Pending
- 2016-12-20 WO PCT/EP2016/081953 patent/WO2017114694A1/en not_active Ceased
- 2016-12-20 CN CN201680082632.4A patent/CN108779175B/zh active Active
- 2016-12-20 JP JP2018552124A patent/JP7091250B2/ja active Active
- 2016-12-20 CA CA3007898A patent/CA3007898A1/en active Pending
- 2016-12-20 US US16/066,688 patent/US11001629B2/en active Active
- 2016-12-20 EP EP16826025.5A patent/EP3397645B1/en active Active
- 2016-12-20 AU AU2016383475A patent/AU2016383475B2/en active Active
-
2021
- 2021-05-10 US US17/315,547 patent/US11891444B2/en active Active
-
2022
- 2022-06-15 JP JP2022096649A patent/JP7551693B2/ja active Active
-
2024
- 2024-02-05 US US18/432,126 patent/US20240174748A1/en active Pending
- 2024-09-04 JP JP2024151952A patent/JP2025000628A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025000628A5 (https=) | ||
| JP7488854B2 (ja) | ヘテロダイマーＦｃ融合サイトカインおよびそれを含む医薬組成物 | |
| JP6839101B2 (ja) | ヘテロ二量体多重特異性抗体フォーマット | |
| JP6904902B2 (ja) | ドメイン交換抗体 | |
| JP2025109759A5 (https=) | ||
| JP6305332B2 (ja) | 多重特異性抗体 | |
| AU2017248671A1 (en) | Trispecific and/or trivalent binding proteins | |
| US20170073415A1 (en) | Novel multispecific molecules and novel treatment methods based on such multispecific molecules | |
| JP2019023184A5 (https=) | ||
| JP2020508655A5 (https=) | ||
| CA2948686A1 (en) | Novel multispecific molecules and novel treatment methods based on such multispecific molecules | |
| JP2016514676A (ja) | 四価二重特異性抗体 | |
| JP2015519375A5 (https=) | ||
| JP2009523459A5 (https=) | ||
| MX2014000816A (es) | Molecula fv de union de antigeno multivalente. | |
| JP2016531100A5 (https=) | ||
| JP2023159379A (ja) | Ｐｄ－１とｖｅｇｆを標的とした四価二重特異性抗体、その製造方法および用途 | |
| CA3173414A1 (en) | Pd-1 agonist multimeric binding molecules | |
| US20240092899A1 (en) | Bispecific antibody | |
| CN116284396A (zh) | NKp46抗体及其用途 | |
| JP2016529213A5 (https=) | ||
| TW201920272A (zh) | 一個需依賴標靶細胞使T細胞接合及活化之不對稱異二聚Fc-ScFv融合抗體形式及其在癌症治療上之應用 | |
| JPWO2020252366A5 (https=) | ||
| JPWO2021139758A5 (https=) | ||
| JPWO2020172598A5 (https=) |